| Revenue growth | Q2 -38% YoY; H1 -10% YoY to ₹159.9 cr |
|---|---|
| Margins | Adj. EBITDA Q2 -₹16.4 cr; H1 ₹18.5 cr vs ₹51.1 cr |
| Demand visibility | Legacy prescriber loyalty; field force still being built |
| Management confidence | No numeric targets; H2 focus on build-out, cost base |
Growth
Q2 revenue -38% YoY to ₹56.1 cr; H1 -10% to ₹159.9 cr. Q2 PAT loss ₹77.5 cr; H1 loss ₹45.3 cr.
Outlook
No numeric guidance. Cost structure to be reflected in Q4 FY27/Q1 FY28; debt reduction via capital infusion planned.
Risks
Exclusive promotion rights terminated (₹61 cr charge); ₹15 cr one-time costs; debt-funded acquisition; elevated opex as field force builds.
Earnings Call Transcript filed with BSE, NSE: EVONILE. Summary written with AI assistance from the document.
Evonile Pharma Ltd: key numbers
- Share price
- ₹1,700.20
- Market cap
- ₹4,198 Cr
- Revenue (annual)
- ₹354.3 Cr
- Net profit (annual)
- ₹93.18 Cr
- P/E (TTM)
- -1052.1×Sector 41.3×
- Promoter holding
- 70.68%+0.00% QoQ
- FII holding
- 1.21%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Evonile Pharma Ltd
All →Evonile Pharma Fund Raise of ₹900 Cr
Evonile Pharma's board approved a partly paid rights issue of up to Rs 900 Crore. A committee will set the issue price, record date and entitlement.
- Value
- ₹900.0 Cr
Evonile Pharma Capital Structure Change
Evonile Pharma's Rights Issue Committee fixed November 11, 2026 as record date for a partly paid rights issue of 1,02,87,832 shares at Rs.860 each. Issue size is Rs.8,847.54 Million, with issue opening November 19, 2026.
- Value
- ₹884.8 Cr
- Execution
- Issue opening 19 Nov 2026 to closing 3 Dec 2026; listing on or about 9 Dec 2026
Evonile Pharma Results Update
Evonile Pharma reported Q2 FY27 revenue of ₹56.1 crore and an EBITDA loss of ₹31.8 crore. H1 FY27 profit after tax was a loss of ₹45.3 crore.
Evonile Pharma Investor Presentation: Key Takeaways
Q2 FY27 revenue fell 38% YoY to ₹56.1 cr, with a ₹77.5 cr net loss including ₹68 cr exceptional items. Transition from single-customer model to independent distribution continues.
Evonile Pharma Q2 FY27 Results: Net Loss of ₹77.5 Cr
Evonile Pharma posted a ₹775.4 million quarterly loss for September 2026 versus profit a quarter earlier. Exceptional items of ₹682.6 million drove the half-year pre-tax loss.
- Key figure
- Net loss ₹77.5 Cr
Novartis India Board Meeting Date
Evonile Pharma will hold a board meeting on November 4, 2026 to approve the rights issue letter of offer. BSE granted in-principle approval for the rights issue.